Boston Scientific Corporation (NYSE:BSX) entered into an agreement to acquire remaining 74% stake in Bolt Medical, Inc. on January 8, 2025. A cash consideration of $443 million will be paid by Boston Scientific Corporation. Boston Scientific Corporation will pay an earnout/contingent payment of $221 million cash.

As part of consideration, $664 million is paid towards common equity of Bolt Medical, Inc. Upon completion, Boston Scientific Corporation will own 100% stake in Bolt Medical, Inc. Boston Scientific is subject to customary closing conditions and anticipates the transaction to be completed in the first half of 2025. Robert T. Ishii, Scott K. Murano, Catherine V. Riley, David H. Hu, Myra A. Sutanto Shen, Alex Key, Christopher A. Paniewski, Brendan Coffman, Kimberley Biagioli, Seth Cowell, Anne E. Seymour, Eva F. Yin, Michael D. Klippert, Michael J. Montfort, Matthew (Matt) Staples, Jason M. Storck, Aren Balabanian, Darby Chan, Susan P. Reinstra, Martin R. Sul and Ryan J. Greecher of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor and Centerview Partners LLC acted as financial advisor to Bolt Medical, Inc.